Mass photometry reaches 2,000-publication milestone as applications expand

Growing body of literature highlights the technology’s value across academic research, therapeutic development, and bioprocessingΒ 

Oxford, UK – 18 Nov 2026 – Refeyn, the pioneer in mass photometry technology, today announced that mass photometry now features in 2,000 scientific publications, marking its growing presence across academic and industrial research.Β 

The milestone follows 500 publications – reached in August 2024 – and more than 1,000 by May 2025. Just eight years after Refeyn was founded, the expanding literature illustrates how scientists are using mass photometry to address analytical challenges across structural biology, protein interactions, antibody development, RNA characterization, and gene therapy.Β 

Mass photometry reaches 2,000-publication milestone: The growth in scientific publications featuring mass photometry highlights its rapid adoption by the scientific community.

2000 Publications by Refeyn

Mass photometry measures individual molecules in solution without labels, revealing sample composition and heterogeneity in minutes using minimal material. It helps scientists investigate molecular interactions, assess sample quality before complex experiments, and make critical decisions during biotherapeutic development.Β 

Published studies demonstrate both established and emerging applications. Researchers have used mass photometry to investigate protein assemblies involved in disease; characterize by-products in bispecific antibody production; measure mRNA length; and quantify empty, partially filled, and full adeno-associated virus (AAV) capsids. Other studies explore new analytical approaches, extending the technology’s capabilities and potential uses.Β 

β€œReaching 2,000 publications is a milestone for the whole mass photometry community,” said Fiona Coats, Chief Product and Marketing Officer at Refeyn. β€œScientists continue to show us the breadth of questions this technology can help answer, from understanding fundamental biological mechanisms to improving how biotherapeutics are developed and characterized. We are proud to support their work and help make these capabilities accessible to more laboratories.” 

Refeyn now has more than 700 systems installed across over 30 countries, with mass photometry used by 23 of the world’s top 25 biopharmaceutical companies. Recent user meetings in France, the USA, and Japan brought together scientists sharing applications across research and bioprocessing – reflecting the community’s continuing exchange of methods and ideas.Β 

Refeyn’s searchable mass photometry publication library brings together scientific articles, preprints and reviews in which the technology has been applied, evaluated or cited.Β